Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Published byJerome Caldwell Modified over 9 years ago

Similar presentations

Presentation on theme: "Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee."— Presentation transcript:

1 Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee 16-17 February 2005

2 1. ALAN HAMPSONADULTA/NEW CALEDONIA/20/99-LIKE (H1N1) WHO, AUSTRALIAELDERA/WYOMING/3/2003 (H3N2) B/BRISBANE/32/2002 2. JOHN WOOD, PH.DADULTA/NEW CALEDONIA/20/99 (H1N1) NIBSC, ENGLANDELDERA/WYOMING/3/2003 (H3N2) B/JIANGSU/10/2003 3. TAKATO ODIGARI, PH.D. ADULTA/NEW CALEDONIA/20/99-LIKE (H1N1) WHO, JAPANELDERA/WYOMING/3/2003 (H3N2) B/SHANGHAI/361/2003 Serum Panels for Serologies

3 4. STEFAN GRAVENSTEIN, M.D.ADULTA/NEW CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA ELDERA/WYOMING/3/2003 (H3N2) MEDICAL SCHOOLCHILDB/JIANGSU/10/2003 5.WILLIAM KOCH, M.D.CHILDA/NEW CALEDONIA/20/99 (H1N1) VIRGINIA COMMONWEALTHA/WYOMING/3/2003 UNIVERSITYB/JIANGSU/10/2003

4 ANTIGENS FOR SEROLOGIES (H1) VACCINE STRAIN A/NEW CALEDONIA/20/99 (H1N1) REPRESENTATIVE CURRENT STRAINS A/BANGKOK/1544/2004 (H1N1) A/FLORIDA/4/2004 (H1N1) A/NETHERLANDS/128/2004 (H1N1) A/NEW CALEDONIA/9/2004 (H1N1) A/OKINAWA/42/2004 (H1N1) A/SAITAMA/78/2004 (H1N1) A/SINGAPORE/14/2004 (H1N1)

5 HI ANTIBODY RESPONSES TO THE H1 COMPONENT 2004-2005 INFLUENZA VACCINE ADULT POPULATION (CBER)

6 HI ANTIBODY RESPONSES TO THE H1 COMPONENT 2004-2005 INFLUENZA VACCINE ELDERLY POPULATION (NIBSC)

7 HI ANTIBODY RESPONSES TO THE H1 COMPONENT 2004-2005 INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)

8 A/NEW CALEDONIA/20/99 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION

9 ANTIGENS FOR SEROLOGIES (H3) VACCINE STRAIN A/WYOMING/3/2003 REPRESENTATIVE CURRENT STRAINS A/BANGKOK/1563/2004 A/CALIFORNIA/7/2004 A/OSAKA/36/2004 A/OSLO/8/2004 A/SHANTOU/1219/2004 A/SINGAPORE/36/2004 A/SINGAPORE/37/2004 A/TENNESSEE/6/2004 A/TOKYO/1035/2004 A/VICTORIA/523/2004

10 HI ANTIBODY RESPONSES TO THE H3 COMPONENT 2004-2005 INFLUENZA VACCINE ADULT POPULATION ( CDC )

11 HI ANTIBODY RESPONSES TO THE H3 COMPONENT 2004-2005 INFLUENZA VACCINE ELDERLY POPULATION (NIBSC)

12 HI ANTIBODY RESPONSES TO THE H3 COMPONENT 2004-2005 INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)

13 A/WYOMING/3/2003 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION

14 ANTIGENS FOR SEROLOGIES (B) VACCINE STRAIN B/BRISBANE/32/2002* B/JIANGSU/10/2003+ REPRESENTATIVE CURRENT STRAINS B/HAWAII/13/2004* B/PHITSANULOK/2053/2004* B/COLORADO/4/2004+ B/FLORIDA/7/2004+ B/FUJIAN/430/2004+ * = HONG KONG/330-LIKE B/LISBON/1/2004+ + = SHANGHAI/361-LIKE B/SHIZUOKA/2/2004+ B/SHIZUOKA/58/2004+ B/VICTORIA/501/2004+

15 HI ANTIBODY RESPONSES TO THE B COMPONENT 2004-2005 INFLUENZA VACCINE ADULT POPULATION (CDC)

16 HI ANTIBODY RESPONSES TO THE B COMPONENT 2004-2005 INFLUENZA VACCINE ELDERLY POPULATION (AUS)

17 HI ANTIBODY RESPONSES TO THE B COMPONENT 2004-2005 INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)

18 B/SHANGHAI/361/2002-LIKE VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION

19 Influenza Vaccine Responses Summary Studies with sera collected after immunization with current vaccines show that: Representative influenza A (H1N1) viruses are well-inhibited A/California/7/2004 (H3N2)-like viruses are poorly inhibited compared to the vaccine strain B/Shanghai/361/2002-like viruses are reasonably well-inhibited but B/Hong Kong/330/2001-like viruses are less well inhibited than the vaccine strains

Download ppt "Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee."

Similar presentations

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Candidate Vaccine Strains and Potency Reagents for Influenza Season
Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.
Candidate Vaccine Strains and Potency Reagents, 2009-2010 Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.
Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.
Adriana Weinberg, MD University of Colorado Denver.

Adriana Weinberg, MD University of Colorado Denver.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.

U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
Influenza Vaccine Manufacturing Industry perspective for 2013-2014 influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.
Influenza Virus Vaccine 2013-2014 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
Influenza Vaccine Manufacturing Industry perspective for 2012-2013 influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.
Influenza Virus Vaccine 2011-2012 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.
Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.
Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,
Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

Similar presentations

Ads by Google